Press Release | Mon Mar 3, 2014 2:05am EST

U.S. FDA Approves Bydureon® Pen (exenatide extended-release for injectable suspension) for Once-Weekly Treatment of Adults with Type 2 Diabetes

* Reuters is not responsible for the content in this press release.